A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） (NCT07519577) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
China120 participantsStarted 2026-05-31
Plain-language summary
This is an open-label, single-arm, multicenter, expansion study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participated in the clinical study of CM512 in patients with Chronic Rhinosinusitis with Nasal Polyposis (Study No. of CM512-102101) .
Exclusion Criteria:
* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.
* Administration of a live attenuated vaccine within 30 days prior to baseline or planning to receive one during the study period.